The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients

• Published in: Atherosclerosis Vol. 199; no. 1; pp. 147 - 153
• Main Authors: Coll, Blai, Cabre, Anna, Alonso-Villaverde, Carlos, Lazaro, Iolanda, Aragonés, Gerard, Parra, Sandra, Girona, Josefa, Masana, Lluis
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier Ireland Ltd 01.07.2008; Elsevier
• Subjects: Adult; Atherosclerosis (general aspects, experimental research); Biological and medical sciences; Biomarkers - blood; Blood and lymphatic vessels; Cardiology. Vascular system; Cardiovascular; FABP4; Fatty Acid-Binding Proteins - blood; Female; HIV infection; HIV Infections - complications; HIV Infections - epidemiology; Humans; Incidence; Lipodystrophy; Lipodystrophy - blood; Lipodystrophy - epidemiology; Lipodystrophy - virology; Male; Medical sciences; Metabolic biomarkers; Metabolic syndrome; Metabolic Syndrome - blood; Metabolic Syndrome - epidemiology; Metabolic Syndrome - virology; Middle Aged; Multivariate Analysis; Risk Factors; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis; Lipodystrophy; FABP4; Metabolic biomarkers; Metabolic syndrome; HIV infection; Endocrinopathy; Immunopathology; Skin disease; Metabolic diseases; Cardiovascular disease; AIDS; Immune deficiency; Infection; Vascular disease; Binding protein; Viral disease; Atherosclerosis; Adipose tissue disorders
• ISSN: 0021-9150; 1879-1484
• DOI: 10.1016/j.atherosclerosis.2007.09.032

Abstract Background The incidence of metabolic abnormalities in HIV-infected patients is increasing. Fatty acid binding protein-4 (FABP4) is an emerging biomarker for metabolic-related disturbances. We aimed to study FABP4 as a marker of metabolic syndrome (MS) or lipodystrophy (LD) in HIV patients. Methods FABP4 plasma concentrations were measured by enzyme-linked immunoassays in 183 HIV-infected patients, enrolled as part of a study aimed at identifying predictors of atherosclerosis. The presence of MS or LD was diagnosed according to standard clinical methods. Univariate and multivariate statistical analyses were performed. Results FABP4 concentration was significantly higher in those patients with either MS or LD criteria than those without any metabolic disturbance. Similarly, FABP4 concentration significantly increased with an increasing of MS features and was strongly correlated with body-mass index, triglycerides, HDL-cholesterol concentrations, insulin and blood pressure. Patients in the highest quartile of FABP4 presented a six-fold increased odds ratio for MS and a three-fold increased odds for LD, adjusted by age, sex, body-mass index and the antiretroviral therapy. Conclusions FABP4 is a strong plasma marker of metabolic disturbances in HIV-infected patients, and therefore, could serve to guide therapeutic intervention in this group of patients.